Vivani Medical (VANI) and Okava Pharmaceuticals said Tuesday they have expanded their partnership in the development of OKV-119 as a treatment for weight management, diabetes and other cardiometabolic diseases to include dogs.
The companies began the collaboration in 2019 to develop OKV-119 for cats.
Financial terms of the collaboration were not disclosed.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.